BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN
BEGIN:VTIMEZONE
TZID:Central Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Central Standard Time
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Central Daylight Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Joyce Lee\, MD\, MS\, and Erin M. Wilfong\, MD\, PhD provide an
  overview of interstitial lung disease (ILD) and some of the diseases that
  can lead to ILD. ILD is the umbrella term used\nfor a large group of dise
 ases characterized by inflammation and/or scarring in the lungs. Patients 
 with some diseases\, such as rheumatoid arthritis\, scleroderma\, myositis
 \, including dermatomyositis and polymyositis (DM and PM)\, sarcoidosis an
 d Sjögren's\nsyndrome\, are at higher risk for ILD. Join us to learn more 
 about how interstitial lung disease (ILD) is diagnosed and treated.&nbsp\;
 \n\nPresenters:\nJoyce Lee\, MD\, MS\nPFF Senior Medical Advisor\nResearch
  and Healthcare Quality\nErin M. Wilfong\, MD\, PhD\nInstructor of Medicin
 e \nRheumatology &amp\; Pulmonary/Critical Care \nVanderbilt University Me
 dical Center\n\n\n\nDeveloped in collaboration with Boehringer Ingelheim P
 harmaceuticals\, Inc.\n
DTEND:20210915T180000Z
DTSTAMP:20260809T171215Z
DTSTART:20210915T170000Z
LOCATION:
SEQUENCE:0
SUMMARY:ILD Day Educational Webinar
UID:RFCALITEM639218743358309539
X-ALT-DESC;FMTTYPE=text/html:<p>Joyce Lee\, MD\, MS\, and Erin M. Wilfong\,
  MD\, PhD provide an overview of interstitial lung disease (ILD) and some 
 of the diseases that can lead to ILD. ILD is the umbrella term used\nfor a
  large group of diseases characterized by inflammation and/or scarring in 
 the lungs. Patients with some diseases\, such as rheumatoid arthritis\, sc
 leroderma\, myositis\, including dermatomyositis and polymyositis (DM and 
 PM)\, sarcoidosis and Sjögren's\nsyndrome\, are at higher risk for ILD. Jo
 in us to learn more about how interstitial lung disease (ILD) is diagnosed
  and treated.&nbsp\;</p>\n<center></center>\n<p style="text-align: center"
 ><strong>Presenters:</strong></p>\n<p style="text-align: center"><strong><
 /strong>Joyce Lee\, MD\, MS<br>\nPFF Senior Medical Advisor<br>\nResearch 
 and Healthcare Quality</p>\n<p style="text-align: center">Erin M. Wilfong\
 , MD\, PhD<br>\nInstructor of Medicine <br>\nRheumatology &amp\; Pulmonary
 /Critical Care <br>\nVanderbilt University Medical Center<br>\n<br>\n</p>\
 n<p style="text-align: center">\nDeveloped in collaboration with Boehringe
 r Ingelheim Pharmaceuticals\, Inc.\n</p>
END:VEVENT
END:VCALENDAR